



## **Manhattan Pharmaceuticals To Present A Rodman & Renshaw Techvest 7th Annual Healthcare Conference**

### **Manhattan Pharmaceuticals To Present A Rodman & Renshaw Techvest 7th Annual Healthcare Conference**

NEW YORK, NY NOV 3 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that Douglas Abel, the Company's President and Chief Executive Officer, will give a presentation on Wednesday, November 9, 2005 at 11:35 a.m. EST at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference. The conference is being held November 7-9, 2005 at the Palace Hotel in New York City.

The presentation will review highlights from Manhattan's development programs including Oleoyl-estrone (OE), an experimental, orally administered small molecule in development for the treatment of obesity. Manhattan's other development programs, PTH (1-34) for psoriasis, and Propofol Lingual Spray for sedation, will also be discussed.

To access the live audio webcast for this presentation please go to <http://www.wsw.com/webcast/rrshq7/mha/> approximately 15 minutes prior to the presentation in order to register and download any necessary software. A replay of the audio presentation will be available following the event at <http://www.manhattanpharma.com>.

#### **About Manhattan Pharmaceuticals, Inc.**

Manhattan Pharmaceuticals, Inc. (AMEX: MHA), a development stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. (<http://www.manhattanpharma.com>)

#### **Contact:**

Nicholas J. Rossettos, CPA  
Chief Financial Officer  
Manhattan Pharmaceuticals, Inc.  
212/582 3950

Thomas Redington  
Redington, Inc.  
203/222-7399  
212/926-1733